Cargando…
Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment
Maintenance peritoneal dialysis (PD) is commonly associated with cardiovascular diseases (CVDs), whose risk is assessed via LDL-C. Nonetheless, oxidized LDL (oxLDL), as being a key component of atherosclerotic lesions, could be also associated with atherosclerosis and related CVDs. However, its pred...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363433/ https://www.ncbi.nlm.nih.gov/pubmed/37302344 http://dx.doi.org/10.1016/j.redox.2023.102762 |
_version_ | 1785076624233857024 |
---|---|
author | Papadea, Polyxeni Kalaitzopoulou, Electra Skipitari, Marianna Varemmenou, Athina Papasotiriou, Marios Papachristou, Evangelos Goumenos, Dimitrios Grune, Tilman Georgiou, Christos D. |
author_facet | Papadea, Polyxeni Kalaitzopoulou, Electra Skipitari, Marianna Varemmenou, Athina Papasotiriou, Marios Papachristou, Evangelos Goumenos, Dimitrios Grune, Tilman Georgiou, Christos D. |
author_sort | Papadea, Polyxeni |
collection | PubMed |
description | Maintenance peritoneal dialysis (PD) is commonly associated with cardiovascular diseases (CVDs), whose risk is assessed via LDL-C. Nonetheless, oxidized LDL (oxLDL), as being a key component of atherosclerotic lesions, could be also associated with atherosclerosis and related CVDs. However, its predictive value for CVDs risk assessment is subject of research studies due to the lack of specific methods to measure oxLDL status from its individual lipid/protein components. In the present study, six novel oxLDL markers, representative of certain oxidative modifications on the LDL protein and lipid components, are measured in atherosclerosis-prone PD patients (39) versus those in chronic kidney disease patients (61) under hemodialysis (HD) and healthy controls (40). LDL from serum of PD, HD and control subjects were isolated and fractionated into cholesteryl esters, triglycerides, free cholesterol, phospholipids and apolipoprotein B100 (apoB100). Subsequently the oxLDL markers cholesteryl ester hydroperoxides (-OOH), triglyceride-OOH, free cholesterol-OOH, phospholipid-OOH, apoB100 malondialdehyde and apoB100 dityrosines were measured. LDL carotenoid levels and LDL particle serum concentration were also measured. The levels of all oxLDL lipid-OOH markers were significantly elevated in PD patients versus control, while the levels of cholesteryl ester-/triglyceride-/free cholesterol-OOH were significantly elevated in PD versus HD patients, regardless of patients’ underlying medical conditions, sex, age, PD type, clinical biochemical markers and medication. It should be noted that all fractionated lipid-OOH levels were inversely correlated with LDL-P concentration, while LDL-P concentration was not correlated with LDL-C in PD patients. Moreover, LDL carotenoids were significantly lower in PD patients versus control. The increased levels of oxLDL status specific markers in both PD and HD patients (compared to control), support a potential prognostic value of oxLDL regarding CVD risk assessment in both patient groups. Lastly, the study introduces the oxLDL peroxidation markers free cholesterol-OOH and cholesteryl ester-OOH as complementary to LDL-P number, and as possible alternatives to LDL-C. |
format | Online Article Text |
id | pubmed-10363433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103634332023-07-25 Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment Papadea, Polyxeni Kalaitzopoulou, Electra Skipitari, Marianna Varemmenou, Athina Papasotiriou, Marios Papachristou, Evangelos Goumenos, Dimitrios Grune, Tilman Georgiou, Christos D. Redox Biol Research Paper Maintenance peritoneal dialysis (PD) is commonly associated with cardiovascular diseases (CVDs), whose risk is assessed via LDL-C. Nonetheless, oxidized LDL (oxLDL), as being a key component of atherosclerotic lesions, could be also associated with atherosclerosis and related CVDs. However, its predictive value for CVDs risk assessment is subject of research studies due to the lack of specific methods to measure oxLDL status from its individual lipid/protein components. In the present study, six novel oxLDL markers, representative of certain oxidative modifications on the LDL protein and lipid components, are measured in atherosclerosis-prone PD patients (39) versus those in chronic kidney disease patients (61) under hemodialysis (HD) and healthy controls (40). LDL from serum of PD, HD and control subjects were isolated and fractionated into cholesteryl esters, triglycerides, free cholesterol, phospholipids and apolipoprotein B100 (apoB100). Subsequently the oxLDL markers cholesteryl ester hydroperoxides (-OOH), triglyceride-OOH, free cholesterol-OOH, phospholipid-OOH, apoB100 malondialdehyde and apoB100 dityrosines were measured. LDL carotenoid levels and LDL particle serum concentration were also measured. The levels of all oxLDL lipid-OOH markers were significantly elevated in PD patients versus control, while the levels of cholesteryl ester-/triglyceride-/free cholesterol-OOH were significantly elevated in PD versus HD patients, regardless of patients’ underlying medical conditions, sex, age, PD type, clinical biochemical markers and medication. It should be noted that all fractionated lipid-OOH levels were inversely correlated with LDL-P concentration, while LDL-P concentration was not correlated with LDL-C in PD patients. Moreover, LDL carotenoids were significantly lower in PD patients versus control. The increased levels of oxLDL status specific markers in both PD and HD patients (compared to control), support a potential prognostic value of oxLDL regarding CVD risk assessment in both patient groups. Lastly, the study introduces the oxLDL peroxidation markers free cholesterol-OOH and cholesteryl ester-OOH as complementary to LDL-P number, and as possible alternatives to LDL-C. Elsevier 2023-06-02 /pmc/articles/PMC10363433/ /pubmed/37302344 http://dx.doi.org/10.1016/j.redox.2023.102762 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Papadea, Polyxeni Kalaitzopoulou, Electra Skipitari, Marianna Varemmenou, Athina Papasotiriou, Marios Papachristou, Evangelos Goumenos, Dimitrios Grune, Tilman Georgiou, Christos D. Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title | Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title_full | Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title_fullStr | Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title_full_unstemmed | Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title_short | Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
title_sort | novel oxidized ldl-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363433/ https://www.ncbi.nlm.nih.gov/pubmed/37302344 http://dx.doi.org/10.1016/j.redox.2023.102762 |
work_keys_str_mv | AT papadeapolyxeni noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT kalaitzopoulouelectra noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT skipitarimarianna noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT varemmenouathina noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT papasotirioumarios noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT papachristouevangelos noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT goumenosdimitrios noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT grunetilman noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment AT georgiouchristosd noveloxidizedldlbasedclinicalmarkersinperitonealdialysispatientsforatherosclerosisriskassessment |